Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For the trial Oncovir linked it s not UCLA.
And you are being ignorant because you fail to understand that ATL-DC (Autlogous Tumor Lysate Dendritic Cell Vaccine) is a main branch of DC vaccines that has been around for over 25 years and used by many.
You can argue if you wish that the specific version used by UCLA "is" DCVax-L. But saying all are is, as I said, ignorant,
Yes, Oncovir discusses combination with ATL-DC on their website. Form this AOO paper, Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients .
No. The defense never asserted 400+ pages were new. They asserted there were 400 total pages of which 144 were entirely new.
The point is that it s not just 17 pages the Defense has to examine. It is 158 pages when the new attached exhibits are counted. So a fair amount data to go through.
No, for 2 reasons.
First, the tax loss carry forward is only about $670M. That is because it expires over time.
Second, companies cannot just by out shells for the TLCF. The IRS has plenty of rules to prevent this.
Every morning at 8:00 OTCN puts in a bid and ask. Is it a signal to the other market makers as to how they will trade that day? It seems so.
How do they "trade"?
OTCN is an ECN. not a MM. They will push the best bid/asks on their books to OTC Link. OTCN makes no trades for themselves.
There is no request for a preliminary injunction. The injunctive relief they are requesting would come into play only after a trial wind by plant ifs.
They added themselves (Northwest) to the list of defendants???
Looks like they screwed something up Friday.
Though it was obvious what you meant, Margin was very wrong about LP not selling her own shares.
In this form 4 from 12/18 LP reported selling 3,558,639 shares and 1,779,320 warrants.
Longs will try to spin this as some forced sale by Tocuan, but those were a smaller amount reported on a different line that she reported at the same time. The codes D/I in "Ownership Form" columns makes clear.
There were also other sales back in the 2015 timeframe where Cognate (fully under LP control) was bartering NWBO shares .
Technically it would be an asset that could be bought by whomever. Though I suspect there might be a claim on it by the mystery "contingency" investors.
Regardless, NWBO is not going BK. They can run at this rate for years while dribbling out the shares you note.
No they did not. They said the pattern of having asks placed while also buying is normal part of their business. They place asks for some customers and also buy for others. Not really complicated.
I missed the footnote about the true-up. That does explain the forward dates.
IMO, there are certain "investors" in these type transactions who at best operate in a grey zone. I am not trying to say who they are as I do not claim to know. But always way to many examples of prices falling around (and in advance) of private offerings.
An endpoint is not just what they are clinically looking at, it includes how they measure and analyze it.
They did though create an endpoint as you suggest. For whatever reason that endpoint (along with the endpoint of 232 vs 99 OS) have not been disclosed.
psPD is a temporary false positive on a scan caused by either tumor necrosis or inflammation. It clears up in a few months,
Why must Merck agree with a PR by NWBO from 2016 on a trial that never launched?
As the PR states, Merck would have supplied the Keytruda if the trial had been run. Yippeee.
The dot connect from the use of liquid biopsies show how totally clueless dstock, DD and others are on the actual subject.
Self contradictory issues in exhibit 6 of the 2nd AC. Probably will not matter at the end of the day, but one would think the crack legal team would do a bit better job of checking the filing.
So NWBO is asserting that in the episodes there are:
. More positive posts in social media
. NWBO selling shares to "investors"
. More selling to retail on OTC Link.
OK, not really surprising.
You misread my post. NWBO submitted two tables that each purport to address the issue. I think the first is fine and that should be enough to get past the MTD.
As expected the 2nd AC compliantly re-writes and explains the table that was in P 289 of the FAC, There are now 2 tables for losses due to last hour spoofing.
The first exhibit (#4) is stock cash sales and consists of 2 sales based on closing price of the previous 10 days.
12.2M shares sold by NWBO 10/12/20 at a price allegedly depressed by $0.008
1.9M shares sold by NWBO 12/12/21 at a price allegedly depressed by $0.019
That sales data looks reasonable, but not exactly very much (about $150K by NWBO's numbers).
The second exhibit (#6) is exchange transactions where stock is exchanged for debt based on 85% of the average of the lowest 5 closes of the past 20 days.
That data s still a bit of stinking mess for 2 reasons. They still have a future close date listed as a spoof in the previous 20 days. On the 7/2/18 exchange they assert the close on 8/1/18 effected the price. But worse, they include any date regardless of it being one of the lowest 5. If the spoof was not one of the lowest 5 it would have no effect in the sale price.
Overall I would expect the next MTD to be dismissed. There will be some yapping about exhibit 6 though. And perhaps some shots about changed assertions.
Regardless of that, the damages look trivial if the Court sticks to the opinion that permanent impairment does not exist.
And just who had motive to sell those days? Perhaps that had an agreement to buy at the lowered price?
After 180 days on under $1 warnings the company can submit a "cure plan" that is to be mplemented in the next 180 days. I have never seen such a plan be anything other than a reverse split.
Best to just get operations on track in the next 2 Qs and see the price rise naturally.